ocuu-crpc trial: enzalutamide vs. flutamide for crpc after bicalutamide
Published 5 years ago • 959 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
1:30
terrain trial of enzalutamide versus bicalutamide for advanced prostate cancer
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:30
terrain: enzalutamide versus bicalutamide for metastatic prostate cancer
-
8:12
the use of abiraterone and enzalutamide against crpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
1:54
dr. plimack discusses trials investigating apalutamide, enzalutamide in m0 crpc
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
5:16
enzamet: enzalutamide for metastatic prostate cancer
-
1:17
dr. neal shore discusses odm-201 in crpc
-
1:50
dr. kohli on the use of enzalutamide and apalutamide in mhspc
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc